Business · 01/10/2004Updated: 10/17/2026 · 1 min read
National Institutes of Health to Consider Co-Exclusive License for Monoclonal Antibodies Against IL-2 Receptor Alpha Chain for Multiple Sclerosis Treatment
Summary
The National Institutes of Health is seeking to grant a co-exclusive license to practice certain inventions related to treating multiple sclerosis, as outlined in several patent applications and international publications filed between 2002 and 2004.